The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 20, 2022
Filed:
Jul. 28, 2020
Applicant:
Zenith Epigenetics Ltd., Calgary, CA;
Inventors:
John Frederick Quinn, Albany, NY (US);
Bryan Cordell Duffy, Glenmont, NY (US);
Shuang Liu, Schenectady, NY (US);
Ruifang Wang, Schenectady, NY (US);
May Xiaowu Jiang, Guilderland, NY (US);
Gregory Scott Martin, Colonie, NY (US);
Gregory Steven Wagner, Foster City, CA (US);
Peter Ronald Young, San Francisco, CA (US);
Assignee:
Zenith Epigenetics Ltd., Calgary, CA;
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/5377 (2006.01); A61K 31/4184 (2006.01); A61K 31/422 (2006.01); A61K 31/423 (2006.01); A61K 31/437 (2006.01); A61K 31/4545 (2006.01); A61K 31/496 (2006.01); A61K 31/497 (2006.01); A61K 31/498 (2006.01); A61K 31/4985 (2006.01); A61K 31/517 (2006.01); A61K 31/52 (2006.01); A61K 45/06 (2006.01); C07D 413/04 (2006.01); C07D 471/04 (2006.01); C07D 473/34 (2006.01); A61P 1/16 (2006.01); A61P 11/00 (2006.01); A61P 1/00 (2006.01); A61P 1/02 (2006.01); A61P 1/04 (2006.01); A61P 1/18 (2006.01); A61P 3/00 (2006.01); A61P 3/04 (2006.01); A61P 3/06 (2006.01); A61P 3/10 (2006.01); A61P 3/12 (2006.01); A61P 5/14 (2006.01); A61P 5/50 (2006.01); A61P 7/04 (2006.01); A61P 7/06 (2006.01); A61P 9/00 (2006.01); A61P 9/04 (2006.01); A61P 9/10 (2006.01); A61P 9/14 (2006.01); A61P 11/02 (2006.01); A61P 11/16 (2006.01); A61P 13/10 (2006.01); A61P 13/12 (2006.01); A61P 15/16 (2006.01); A61P 17/00 (2006.01); A61P 17/02 (2006.01); A61P 17/06 (2006.01); A61P 19/02 (2006.01); A61P 19/06 (2006.01); A61P 19/08 (2006.01); A61P 21/00 (2006.01); A61P 21/04 (2006.01); A61P 25/00 (2006.01); A61P 25/14 (2006.01); A61P 25/16 (2006.01); A61P 25/18 (2006.01); A61P 25/24 (2006.01); A61P 25/28 (2006.01); A61P 27/02 (2006.01); A61P 27/04 (2006.01); A61P 27/16 (2006.01); A61P 29/00 (2006.01); A61P 31/04 (2006.01); A61P 31/12 (2006.01); A61P 31/14 (2006.01); A61P 31/18 (2006.01); A61P 31/20 (2006.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01); A61P 37/00 (2006.01); A61P 37/06 (2006.01); A61P 37/08 (2006.01); A61P 43/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/5377 (2013.01); A61K 31/4184 (2013.01); A61K 31/422 (2013.01); A61K 31/423 (2013.01); A61K 31/437 (2013.01); A61K 31/4545 (2013.01); A61K 31/496 (2013.01); A61K 31/497 (2013.01); A61K 31/498 (2013.01); A61K 31/4985 (2013.01); A61K 31/517 (2013.01); A61K 31/52 (2013.01); A61K 45/06 (2013.01); C07D 413/04 (2013.01); C07D 471/04 (2013.01); C07D 473/34 (2013.01); Y02A 50/30 (2018.01);
Abstract
The invention relates to substituted bicyclic compounds, which are useful for inhibition of BET protein function by binding to bromodomains, pharmaceutical compositions comprising these compounds, and use of the compounds and compositions in therapy.